In addition, HER2 gene deletion (HER2/CEP17 ratio ≤0.8) was detected in 9% (2/22) of tumor tissues, and gain of chromosome 17 centromere (CEP17 ≥ 3) was observed in 50% (11/22) of tumor tissues. This evidence concerns the gene ERBB2 and neoplasm.